Home /
Active Studies
Evaluation of the effectiveness of Abrysvo® vaccine in pregnant women to prevent RSV hospitalization in their infants.
This is a collaborative study designed by iTrials - Equipo Ciencia, the Hub for Innovation in Health Policy and Equity (HubIPSE) of UNSAM, which aims to estimate the real-world impact and effectiveness of the RSVpreF vaccine (Abrysvo®, Pfizer) applied to pregnant women in the second and third trimester.
This program, called BERNI, demonstrated a high effectiveness of the vaccine in preventing hospitalizations for severe RSV-associated Acute Respiratory Infections (ARIb) during the first six months of life. This real-world and, moreover, local evidence from the first season of the program confirms and supports the findings of the MATISSE Phase 3 clinical trial.
The results of this study can be found in The Lancet.
Team Science conducted the study that demonstrated the efficacy of one of the first vaccines against RSV in older adults. Currently, the administration of a second dose of the vaccine, two years after the initial one, is being evaluated in a group of the same volunteers who participated in that first stage. The objective of this new phase is to analyze the immunological response in previously vaccinated persons.
Nasal vaccine against respiratory syncytial virus in infants, children and adolescents
Team Science is conducting the PEARL study, which seeks to evaluate the efficacy, immunogenicity and safety of a live attenuated nasal vaccine against respiratory syncytial virus in infants and children 6 to 22 months of age.
Vaccines against SARS-CoV-2 virus in infants, boys and girls
Team Science is conducting the ROVER study, which seeks to evaluate the safety and immunogenicity of an mRNA vaccine booster for COVID-19 variants in participants aged 6 months to 5 years.
This study seeks to obtain more information about whether the vaccine is safe when administered to infants and children at the same dose as the initial vaccination and how the immune response is when given as a booster. how the immunological response is when it is administered as a booster.
Economic impact of severe respiratory syncytial virus disease in infants and young children in Argentina, Brazil and Colombia.
We are conducting a multicenter observational study whose main objective is to estimate the direct and indirect financial and economic costs of severe acute illness caused by RSV for the health system, households and society in three representative Latin American countries.
The study also seeks to compare the specific direct and indirect costs of RSV-associated ARI with those of non-RSV-associated ARI.
Research study of a vaccine against COVID-19 in pediatrics.
Currently, Team Science is enrolling children six (6) months to five (5) years of age in a study called ROVER, which is evaluating the efficacy and safety of a booster dose of a COVID-19 vaccine approved for the pediatric population.
Your son or daughter may participate if he or she is in good general health and has had at least two doses of COVID-19 vaccine.
Impact of vaccines
COVID-19 vaccines have been shown to be effective in preventing SARS-CoV-2 infection and its complications. This favorable impact has been confirmed in adults and children globally. Recommendations from pediatric and infectious disease societies are based on the fact that the benefits of vaccination far outweigh the potential risks.
Although vaccinated individuals can become infected, the clinical pictures tend to be milder, with less possibility of prolonged manifestations and a more robust and long-lasting immunity. A major reason for vaccinating the pediatric population is to prevent complications from infection with this virus.
Frequently Asked Questions
Are COVID-19 vaccines safe and effective for children?
Yes, the vaccines have been approved for use in children and have been shown to be safe and effective. Clinical studies and real-world data support their safety and efficacy in preventing serious illness and hospitalization. Evidence from millions of vaccinated children confirms that vaccines reduce the risk of infection and serious illness. After demonstrating safety and efficacy in adults, studies in the pediatric population detected no serious safety concerns. The National Administration of Drugs, Food and Medical Technology (ANMAT), the U.S. Food and Drug Administration (FDA) and the Centers for Disease Control and Prevention (CDC) and independent experts continue to closely monitor vaccine safety.
What do we know about COVID-19 in newborns and pregnant women?
Newborns can become infected during delivery or through exposure to sick caregivers. Infection is more severe in pregnant women, who are at greater risk of requiring intensive care, mechanical ventilation and other therapies. In addition, in these cases, newborns are at increased risk of prematurity, mortality at birth and other complications. Therefore, vaccination in pregnant women is important along with other vaccines such as influenza, tetanus, whooping cough and respiratory syncytial virus (RSV). Vaccination protects both the mother and the newborn.
Can children easily transmit COVID-19 to others?
Yes, children can transmit COVID-19 to others, although the ease of transmission may vary. It is important to follow prevention measures to reduce the risk of spread. Also, vaccination acts as a barrier to contain transmission to more vulnerable people (such as older adults or immunosuppressed persons).
From what age can children be vaccinated against COVID-19?
The minimum age for vaccination varies according to the vaccine and the regulations of each country. In Argentina, vaccines are authorized from 6 months of age.
Is the COVID-19 vaccine part of the National Immunization Schedule and is it mandatory?
Vaccination against COVID-19 is not part of the National Vaccination Calendar and is not mandatory in Argentina. In the pediatric population, it is recommended from the age of 6 months, especially if there are medical conditions that increase the risk of severe forms of COVID-19.
